CINECA IRIS Institutional Research Information System

FODDAI, SILVIA GRAZIETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.410
AS - Asia 1.236
EU - Europa 1.103
SA - Sud America 308
AF - Africa 41
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.105
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.277
SG - Singapore 509
IT - Italia 453
CN - Cina 370
BR - Brasile 187
MX - Messico 99
ES - Italia 98
DE - Germania 90
IE - Irlanda 85
KR - Corea 73
IN - India 72
VN - Vietnam 47
FR - Francia 46
FI - Finlandia 45
SE - Svezia 44
GB - Regno Unito 40
HK - Hong Kong 35
AR - Argentina 34
RU - Federazione Russa 33
ID - Indonesia 27
PL - Polonia 25
CO - Colombia 24
JP - Giappone 24
RO - Romania 22
CA - Canada 21
AT - Austria 20
EC - Ecuador 19
NL - Olanda 17
TR - Turchia 17
CL - Cile 14
PE - Perù 14
CH - Svizzera 11
TW - Taiwan 11
UA - Ucraina 11
EG - Egitto 10
MA - Marocco 9
PT - Portogallo 8
BE - Belgio 7
HU - Ungheria 7
IQ - Iraq 7
IR - Iran 7
VE - Venezuela 7
AU - Australia 6
DK - Danimarca 6
DZ - Algeria 6
GR - Grecia 6
IL - Israele 6
MT - Malta 6
BD - Bangladesh 5
CZ - Repubblica Ceca 5
SA - Arabia Saudita 5
TN - Tunisia 5
DO - Repubblica Dominicana 4
RS - Serbia 4
SI - Slovenia 4
CR - Costa Rica 3
KE - Kenya 3
MY - Malesia 3
PK - Pakistan 3
PY - Paraguay 3
SN - Senegal 3
UY - Uruguay 3
AM - Armenia 2
BG - Bulgaria 2
BO - Bolivia 2
HR - Croazia 2
JM - Giamaica 2
LV - Lettonia 2
NI - Nicaragua 2
NO - Norvegia 2
PH - Filippine 2
TH - Thailandia 2
UZ - Uzbekistan 2
ZA - Sudafrica 2
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CU - Cuba 1
CY - Cipro 1
EU - Europa 1
GE - Georgia 1
GN - Guinea 1
GT - Guatemala 1
LT - Lituania 1
MU - Mauritius 1
NG - Nigeria 1
NP - Nepal 1
OM - Oman 1
QA - Qatar 1
SR - Suriname 1
Totale 4.105
Salva come PNG Salva come JPEG
Città #
Singapore 294
Santa Clara 198
Chandler 146
Turin 127
Beijing 89
Dublin 85
Ashburn 83
Seoul 72
Sesto San Giovanni 63
Hefei 57
Ann Arbor 45
Torino 44
New York 37
Bengaluru 35
Columbus 33
Los Angeles 33
Dallas 32
Fairfield 32
Hong Kong 30
Medford 30
Nyköping 30
São Paulo 29
Milan 27
Jakarta 23
Madrid 23
Rome 23
Wilmington 23
Munich 22
Mexico City 20
Giussano 19
Hangzhou 19
Paris 19
Helsinki 17
Princeton 17
Ho Chi Minh City 16
Córdoba 15
Vienna 15
Chicago 13
Shanghai 13
Buffalo 12
Chengdu 12
Houston 12
Lappeenranta 12
Lima 12
Redondo Beach 12
The Dalles 12
Frankfurt am Main 11
Seattle 11
Tokyo 11
Turku 11
Bologna 10
Falls Church 10
Hebei 10
Wuhan 10
Düsseldorf 9
Guiyang 9
Hyderabad 9
Nuremberg 9
Redwood City 9
Denver 8
Dong Ket 8
Hanoi 8
Mumbai 8
Quito 8
Santiago 8
Ankara 7
Barcelona 7
Boardman 7
Brasov 7
Cambridge 7
Cuenca 7
Guadalajara 7
Jacksonville 7
Lisbon 7
Athens 6
Berlin 6
Boston 6
Brasília 6
Bucharest 6
Guangzhou 6
Gustavo Adolfo Madero 6
Mexico 6
Querétaro 6
San Diego 6
Seville 6
Sheffield 6
Silver Spring 6
Toronto 6
Vitória 6
Wroclaw 6
Agliè 5
Amsterdam 5
Bari 5
Bogotá 5
Brussels 5
Bucaramanga 5
Budapest 5
Cairo 5
Chongqing 5
Cuauhtémoc 5
Totale 2.418
Salva come PNG Salva come JPEG
Nome #
Treatment of antiphospholipid syndrome 381
Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome 376
Thermography in systemic sclerosis patients and other rheumatic diseases: Diagnosis, disease activity assessment, and therapeutic monitoring 285
Clinical manifestations in patients with antiphospholipid antibodies: Beyond thrombosis and pregnancy loss 211
Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients 154
Tailoring tofacitinib oral therapy in rheumatoid arthritis: The TuTORApp—a usability study 132
Impact of the new 2019 EULAR/ACR classification criteria for Systemic Lupus Erythematosus in a multicenter cohort study of 133 women with undifferentiated connective tissue disease 128
Quality of life in patients with antiphospholipid antibodies differs according to antiphospholipid syndrome damage index (DIAPS) 128
Improving the clinical accuracy in patients with antiphospholipid antibodies using anti-phosphatidylserine/prothrombin and anti-beta2 glycoprotein I domain and particle-based multi-analyte technology 126
Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS) 117
2023 ACR/EULAR classification criteria in existing research cohorts: an international study 116
Antiphosphatidylserine/Prothrombin Antibodies: An Update on Their Association with Clinical Manifestations of Antiphospholipid Syndrome 110
A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution 110
Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies 109
Reducing the diagnostic delay in Antiphospholipid Syndrome over time: a real world observation 100
Genetic factors in antiphospholipid syndrome: Preliminary experience with whole exome sequencing 93
Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study 93
"How we treat" clinical dilemmas in antiphospholipid syndrome: A case-based approach 93
The prevalence of antiphospholipid antibodies in women with late pregnancy complications and low-risk for chromosomal abnormalities 92
ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the APS ACTION Clinical Database and Repository 90
Detection of Autoantibodies in Saliva as New Avenue for the Diagnosis and Management of Autoimmune Patients 87
Disease activity at conception predicts lupus flare up to two years after birth: A multicentre long term follow-up study 76
Assessing the steroid-sparing effect of biological agents in randomized controlled trials for lupus: a scoping review 75
Validation of the particle-based multi-analyte technology for detection of anti-phosphatidylserine/ prothrombin antibodies 74
The Interconnection Between Systemic Lupus Erythematosus and Diet: Unmet Needs, Available Evidence, and Guidance—A Patient-Driven, Multistep-Approach Study 73
Assessing the cardiovascular risk in patients with systemic lupus erythematosus: QRISK and GAPSS scores head-to-head 72
Finding the Needle in the Haystack: Serological and Urinary Biomarkers in Behçet’s Disease: A Systematic Review 70
Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS) (vol 122, pg 1612, 2022) 65
Thrombin generation assay and lupus anticoagulant synergically distinguish populations of patients with antiphospholipid antibodies 64
New Frontiers in Autoimmune Diagnostics: A Systematic Review on Saliva Testing 61
Thrombosis and APS: Lessons Learned from Another Black Swan Tale 60
Type I interferon pathway activation across the antiphospholipid syndrome spectrum: associations with disease subsets and systemic antiphospholipid syndrome presentation 59
Serum Biomarkers of Renal Fibrosis: A Systematic Review 58
Reply to comment on: Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients 49
Pursuing appropriateness in antiphospholipid antibodies testing: Feasibility study with a reflex test approach for anti-β2GPI I domain 47
Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab 47
Pediatric Presentation of Antiphospholipid Syndrome: A Review of Recent Literature With Estimation of Local Prevalence 41
Reasons for Breastfeeding Avoidance: A Multicenter Insight in Mothers With Systemic Lupus Erythematosus 30
Green Lab Insights: multimodal experimental model, testing appropriateness and sustainability awareness 20
Totale 4.172
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.070
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.070
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202185 0 0 0 0 0 9 2 14 20 10 8 22
2021/2022375 17 35 34 13 43 30 26 17 28 19 47 66
2022/2023703 57 66 40 54 69 128 63 54 51 23 60 38
2023/2024698 61 73 66 35 80 73 37 41 19 55 37 121
2024/20251.229 55 58 46 105 275 98 75 81 94 81 95 166
2025/20261.028 182 158 133 309 213 33 0 0 0 0 0 0
Totale 4.172